Patents by Inventor Satomi IMAIDE

Satomi IMAIDE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY
    Publication number: 20240327342
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Application
    Filed: June 14, 2024
    Publication date: October 3, 2024
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide WATANABE, Kensuke KUSUMI, Satomi IMAIDE, Toshimitsu ENDO, Takaki KOMIYA, Naomi TSUBURAYA
  • IMPROVED SMALL MOLECULES
    Publication number: 20240252654
    Abstract: This invention particularly relates to trifunctional PROTACs of formula I as described herein which bind to a protein within the Bromo- and Extra-Terminal (BET) family of proteins, and especially to PROTACs including small molecule E3 ubiquitin ligase protein binding ligand compounds which induce preferential degradation of the BRD2 protein within the bromodomain of the BET family of proteins.
    Type: Application
    Filed: October 19, 2021
    Publication date: August 1, 2024
    Inventors: Alessio Ciulli, Andrea Testa, Chiara Maniaci, Nikolai Makukhin, Satomi Imaide, Danette Daniels, Kristin Riching
  • Compounds having S1P5 receptor agonistic activity
    Patent number: 12049445
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Grant
    Filed: November 8, 2021
    Date of Patent: July 30, 2024
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide Watanabe, Kensuke Kusumi, Satomi Imaide, Toshimitsu Endo, Takaki Komiya, Naomi Tsuburaya
  • COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY
    Publication number: 20220055986
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Application
    Filed: November 8, 2021
    Publication date: February 24, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide WATANABE, Kensuke KUSUMI, Satomi IMAIDE, Toshimitsu ENDO, Takaki KOMIYA, Naomi TSUBURAYA
  • Compounds having S1P5 receptor agonistic activity
    Patent number: 11198672
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: December 14, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide Watanabe, Kensuke Kusumi, Satomi Imaide, Toshimitsu Endo, Takaki Komiya, Naomi Tsuburaya
  • COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY
    Publication number: 20210087141
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Application
    Filed: February 21, 2019
    Publication date: March 25, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide WATANABE, Kensuke KUSUMI, Satomi IMAIDE, Toshimitsu ENDO, Takaki KOMIYA, Naomi TSUBURAYA